Publication Year

Thompson C, Perry C, Gaylor D, Tachovsky A, Burkhalter B, Haws L. 2011. Derivation of an oral reference dose and drinking water screening level for sulfolane using benchmark dose modeling. Presented at the Society of Toxicology’s 50th Annual Meeting, March 6-10, Washington, D.C.

Thompson CM, Proctor DM, Haws LC, Hebert CD, Grimes SD, Shertzer HG, Kopec AK, Hixon JG,  Zacharewski TR, Harris MA. 2011. Investigation of the mode of action underlying the tumorigenic response induced in B6C3F1 mice exposed orally to hexavalent chromium. Toxicol Sci 123(1): 58-70.

Bogen KT, Brorby GP, Berman DW, Sheehan PJ, Floyd M.  2011. Measuring mixed cellulose ester (MCE) filter mass under variable humidity conditions.  Ann Occup Hyg 55(5)485-494.

Mounho B. 2011. Definitions and standards for the approval of biosimilar products. Presented at American College of Toxicology Annual Meeting, November, Phoenix, AZ.

Urban J, Fitzgerald L, Burkhalter B, Staskal D, Harris M, Haws L. 2011. BTEX serum levels in the general U.S. population: An analysis of 2003-2004 NHANES dataset. Presented at the Society of Toxicology’s 50th Annual Meeting, March 6-10, Washington, D.C.

Thompson CM, Haws LC, Harris MA, Gatto NM, Proctor DM. 2011. Application of the U.S. EPA mode of action framework for purposes of guiding future research: A case study involving the oral carcinogenicity of hexavalent chromium. Toxicol Sci 119(1):20-40.

Bussiere J, Leach M, Price K, Mounho B, Lightfoot-Dunn R. 2011. Survey results on the use of the tissue cross-reactivity immunohistochemistry assay. Reg Toxicol Pharm 59(3):493-505.

Diliberto JJ, Sirinek L, Burkhalter B, Wikoff DS, Hixon G, Becker J, Patterson DG, Turner W, Tachovsky JA, Birnbaum LS, Haws LC. 2011. Endometriosis in a cohort of women living in the Kanawha River Valley in West Virginia: Blood levels of non-dioxin-like PCBs and relationship with BMI and age. Presented at Dioxin 2011, August 21-25, Brussels, Belgium.

Oller A, Henderson RG. 2011. Bioaccessibility testing and its application to read-across for hazard assessment and risk characterisation of metals. Annual meeting of the Belgian Society for Toxicology and Ecotoxicology (BelTox).

Brorby GP, Sheehan PJ, Berman DW, Bogen KT, Holm SE. 2011. Potential artifacts associated with historical preparation of joint compound samples and reported airborne asbestos concentrations.  J Occup Environ Hyg 8(5):271–278.

Haws LC, DeVito MJ, Walker NJ, Harris MA, Tachovsky JA, Birnbaum LS, Farland WH, Wikoff DS. 2011. Development of a consensus-based weighting framework for evaluating estimates of relative potency for dioxin-like compounds that includes consideration of data from human cells. Presented at Dioxin 2011, August 21-25, Brussels, Belgium.

Semeraro A, Patriarca M, Taylor A, Henderson R, Bates H. 2011. Nickel kinetics after oral exposure: Urinary excretion. IUPAC 4th International Symposium for Trace Elements in Food.

Haws LC, Fitzgerald L, Burkhalter B, Harris M, Wikoff DS. 2011. Assessment of the US EPA’s proposed toxicological values for TCDD for regulation of dioxin-like compounds in foods: Bridging the science divide in a global market. Presented at Dioxin 2011, August 21-25, Brussels, Belgium.

Gujral JS, Proctor DM, Su SH, and Fedoruk JM. 2011. Water adherence factors for human skin. Risk Analysis 31(8):1271-1280.

Rowlands JC, Urban J, Wikoff DS, Budinsky R. 2011. The presence and estimated functional effect of single nucleotide polymorphisms at the AIP, ARNT, HSP90AA1, AND HSP90AB1 loci in the human population. Presented at Dioxin 2011, August 21-25, Brussels, Belgium.

Miletich J, Eich G, Grampp G, and Mounho B. 2011. Guiding principles for a global “patients first” standard. mAbs 3(3):318-325.

Thomas RS, Rowlands JC, Budinsky RA, Thompson CM, Urban JD. Dombkowski, A. 2011. Genomic approaches for relative potency assessment. Presented at Dioxin 2011, August 21-25, Brussels, Belgium.

Rowlands JC, Urban JD, Wikoff DS, Budinsky RA. 2011. An evaluation of single nucleotide polymorphisms in the human aryl hydrocarbon receptor-interacting protein (AIP) gene. Drug Metab Pharmacokinet 26(4):431-439.

Wikoff DS, Thompson C, Walker N, DeVito M, Harris M, Birnbaum L, Haws L. 2011. Derivation of relative potency estimates using benchmark dose modeling: A case study with TCDF. Presented at Dioxin 2011, August 21-25, Brussels, Belgium.

Sheehan PJ, Brorby GP, Berman DW, Bogen KT, Holm SE. 2011. Chamber for testing asbestos-containing products:  Validation and testing of a re-created chrysotile-containing joint compound.  Ann Occup Hyg 55(7):797-809.

Budinsky R, Urban J, Rowlands JC. 2011. An evaluation of single nucleotide polymorphisms in the human aryl hydrocarbon receptor nuclear translocator gene. Presented at the Society of Toxicology’s 50th Annual Meeting, March 6-10, Washington, D.C.

Ceder R, Merne M, Nilsson J-A, Staab C, Höög J-O, Thompson CM, Grafström RC. 2011.  Toxicogenomic profiling of formaldehyde-exposed normal and transformed human oral keratinocytes. Presented at the Society of Toxicology’s 50th Annual Meeting, March 6-10, Washington, D.C.

Fitzgerald L, Burkhalter B, Urban J, Staskal D, Harris M, Haws L. 2011. VOC serum levels in the general U.S. population: An analysis of the 2003-2004 NHANES dataset. Presented at the Society of Toxicology’s 50th Annual Meeting, March 6-10, Washington, D.C.

Haws L, Proctor D, Thompson C, Harris M. 2011. Research plan to fill data gaps in the mode of action for cancer risk assessment of hexavalent chromium in drinking water. Presented at the Society of Toxicology’s 50th Annual Meeting, March 6-10, Washington, D.C.

Tichomirowa MA, Bariler A, Daly AF, Jaffrain-Rea M-L, Ronchi CL, Yaneva M, Urban JD, Petrossians P, Elenkova AP, Tabarin A, Desailloud R, Maiter D, Schürrmeyer T, Cozzi R, Theodoropoulou M, Sievers C, Bernabeu I, Naves LA, Chabre O, Fajardo Montañana C, Hana V, Halaby G, Delemer B, Labarta JI, Sonnet E, Ferrandez A, Hagelstein MTS, Caron P, Stalla GK, Bours V, Zacharieva S, Spada A, Brue T, Beckers A. 2011. High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas. Eur J Endocrinol 165(4):509-515.

Urban JD, Rowlands JC, Budinsky RA. 2011. Single nucleotide polymorphisms in the human aryl hydrocarbon receptor nuclear translocator (ARNT) gene. Drug Metab Pharmacokinet 26(6):637-645.

Henderson RG, Cappellini D, Seilkop S, Oller A, Bates H. 2011. Bioaccessibility-based read-across assessment of nickel compounds for oral systemic toxicity. Presented at the Society of Toxicology’s 50th Annual Meeting, March 6-10, Washington, D.C.

Kim S, Thompson CM, Kopec AK, Harris MA, Zacharewski TR. 2011. Comparison of basal and CrVI-mediated solute carrier gene expression in rodent duodenal epithelium. Presented at the Society of Toxicology’s 50th Annual Meeting, March 6-10, Washington, D.C.

Buckley L, Chapman K, Burns Naas LA, Todd M, Martin P, Lansita J. 2011. Considerations regarding nonhuman primate use in safety assessment of biopharmaceuticals. Int J Toxicol 30(5):583-590.

Proctor D, Haws L,Thompson C, Harris M. 2011. Use of mode of action and pharmacokinetics to inform the cancer risk assessment of ingested Cr(VI): A case study. Presented at the Society of Toxicology’s 50th Annual Meeting, March 6-10, 2011. Washington, D.C.

Proctor D, Meek B. 2011. Using mode of action data to guide quantitative cancer risk assessment: A case study of hexavalent chromium in drinking water. Presented at the Society of Toxicology’s 50th Annual Meeting, March 6-10, Washington, D.C.

Staskal-Wikoff D, Budinsky R, Rowlands JC. 2011. Single nucleotide polymorphisms in the human aryl hydrocarbon receptor interacting protein (AIP) gene from six ethnic populations. Presented at the Society of Toxicology’s 50th Annual Meeting, March 6-10, Washington, D.C.